Bulletin from the 2021 Annual General Meeting of Spago Nanomedical AB (publ)
The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 5, 2021, at which the AGM resolved to approve the income statement and balance sheet for 2020 and discharge the Board members and the CEO from liability for the financial year 2020.
The following resolutions were also passed at the AGM:
Disposition of results
In accordance with the Board's proposal, no dividend will be paid and KSEK 47,966 are carried forward.
Election of board and board fees
The Board shall consist of five ordinary members and no deputies. Peter Leander, Sten Nilsson, Kari Grønås, Eugen Steiner and Nicklas Westerholm were re-elected as members of the Board for the period until the end of the next AGM. Eugen Steiner was re-elected Chairman of the Board.
Board fees for the period until the end of the next AGM shall be SEK 200,000 (unchanged) to the Chairman of the Board and SEK 95,000 (unchanged) to each of the other Board members.
Instructions for the nomination committee
The AGM resolved on instructions for the Nomination Committee's work and composition in accordance with the proposal presented in the notice convening the AGM.
Election of auditor and auditor fee
In accordance with the Nomination Committee's proposal, BDO Mälardalen AB was re-elected as auditor for the period until the end of the AGM in 2022. Authorized Public Accountant Jörgen Lövgren will be primarily responsible for the audit. Fees to the auditor shall be paid in accordance with approved invoices.
Authorization for the Board to make decisions on new share issues
For the period until the next AGM, the Board was authorized to, on one or more occasions, with or without deviation from the shareholders' preferential rights, decide on a new share issue by cash payment, non-cash payment or payment by set-off of a maximum of 20 percent of the total number of shares in the company at the time of exercising the authorization, in order to enable capital raising if market conditions were deemed appropriate and/or to broaden Spago Nanomedical's ownership base by offering financial and industrial investors to invest in the company.
Resolution on amendment of the Articles of Association
The AGM resolved, in accordance with the Board's proposal, to introduce a provision on proxy collection and postal voting. Furthermore, the AGM resolved to amend the Articles of Association so that the auditor can be elected for a period of one, two, three or four years.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, email@example.com.
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, firstname.lastname@example.org.